Monoclonal antibodies that target checkpoint molecules on either T cells or tumor cells (termed checkpoint inhibitors—see table Some Immunotherapeutic Agents in Clinical Use) are used to prevent downregulation of antitumor responses and effectively treat some heretofore resistant cancers.